Can you discuss the reductions in MACE events reported in the PCSK9 outcome trials and how they shape the benefit/safety equation for the use of alirocumab and evolocumab in high-risk patients, including diabetics, for secondary prevention of ASCVD?
Can you discuss the reductions in MACE events reported in the PCSK9 outcome trials and how they shape the benefit/safety equation for the use of alirocumab and evolocumab in high-risk patients, including diabetics, for secondary prevention of ASCVD?
Created by
Presenter
Deepak Bhatt, MD, MPH, FACC, FAHA, FSCAI, FESC
Executive Director of Interventional Cardiovascular ProgramsBrigham and Women’s HospitalHeart and Vascular CenterProfessor of Medicine, Harvard Medical SchoolBoston, USA